Brainstorm Cell (NASDAQ: BCLI) grants executive 900K stock options
Rhea-AI Filing Summary
Brainstorm Cell Therapeutics Inc. reported that Executive Chairman Peter Joe Pitts received a grant of 900,000 stock options on July 24, 2026. The options have a $1.00 exercise price, are exercisable for 900,000 common shares, expire on July 24, 2036, and vest over 48 months subject to continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Pitts Peter Joe
Role
Executive Chairman
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 900,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 900,000 shares (Direct)
Footnotes (2)
- F1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
- F2. The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Key Figures
Stock options granted: 900,000 options
Exercise price: $1.00 per share
Underlying common shares: 900,000 shares
+4 more
7 metrics
Stock options granted
900,000 options
Grant to Executive Chairman Peter Joe Pitts on July 24, 2026
Exercise price
$1.00 per share
Per-share exercise price for the granted stock options
Underlying common shares
900,000 shares
Number of common shares underlying the option grant
Expiration date
2036-07-24
Date on which the options expire if unexercised
Vesting period
48 months
Total period over which the granted options vest
Initial vesting portion
25%
Portion of options vesting on July 24, 2027
Ongoing monthly vesting fraction
1/48th
Fraction of the grant vesting monthly after July 24, 2027
Key Terms
Stock Option (Right to Buy), 2014 Stock Incentive Plan, vest over 48 months, underlying security
4 terms
Stock Option (Right to Buy) financial
"The security title is listed as "Stock Option (Right to Buy)"."
2014 Stock Incentive Plan financial
"Granted under the Issuer's 2014 Stock Incentive Plan."
vest over 48 months financial
"The stock options vest over 48 months, with 25% vesting on July 24, 2027"
underlying security financial
"The underlying security title is Common Stock with 900000.0000 shares."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider equity award did BCLI grant to Executive Chairman Peter Joe Pitts?
Brainstorm Cell Therapeutics granted Executive Chairman Peter Joe Pitts 900,000 stock options to buy common shares at $1.00 per share. These options expire on July 24, 2036 and were issued as compensation under the company’s 2014 Stock Incentive Plan.
What are the key terms of Peter Joe Pitts’ BCLI stock options?
Peter Joe Pitts’ options cover 900,000 common shares at a $1.00 exercise price and expire on July 24, 2036. The grant is structured as a long-term incentive under the 2014 Stock Incentive Plan, aligning potential value with company performance over time.
How do the BCLI options granted to Peter Joe Pitts vest over time?
The options vest over 48 months, with 25% vesting on July 24, 2027 and the remaining 75% vesting in 1/48th increments monthly. Vesting is conditioned on Peter Joe Pitts remaining employed through each applicable vesting date.
How many BCLI derivative securities does Peter Joe Pitts hold after this grant?
After this transaction, Peter Joe Pitts holds 900,000 stock options linked to Brainstorm Cell Therapeutics common stock. This reflects the full amount of the new grant, as the report shows 900,000 derivative securities owned following the award.
What type of security is involved in the recent BCLI insider transaction?
The transaction involves a Stock Option (Right to Buy) derivative security linked to Brainstorm Cell Therapeutics’ common stock. Each option grants the right to purchase one common share at $1.00, subject to the vesting schedule and expiration terms.